PPHM - Peregrine Pharmaceuticals

[arlbbcrc29]

Moving Averages:

MA10: 1.03
MA13: 1.02
MA50: 0.98
MA200: 1.08

Vol Average 50-day: 990,800
Vol Average 200-day: 920,000
52-wk high(4/4/2005): $ 1.64
52-wk low(12/21/2005): $ 0.88

[BertOMahon]

Reported Date
Insider
Shares
Transaction
Trade Date
Avg. Price
Total
Return (6 Mo)
SEC Filing
Today 6:42 PM SWARTZ ERIC S
Director 10,000 Market Purchase 27-Jan-06 $1.15 $11,500.00 1% view
27-Jan-06 4:45 PM SWARTZ ERIC S
Director 10,000 Market Purchase 26-Jan-06 $1.12 $11,200.00 4% view
06-Jan-06 6:03 PM SWARTZ ERIC S
Director 12,000 Market Purchase 05-Jan-06 $0.91 $10,918.80 27% view




ok buddy Im in now

[Asuqytrau]

Wow what a day ... closed @ 1.54 on BIG RUMORS

:: Feb 2, 2006 (JAGfn.com via COMTEX) -- (GSK) (PPHM) Rumor that PEREGRINE PHARMA INC (NasdaqSC:PPHM) will announce a partnership with GLAXOSMITHKLINE PLC (NYSE:GSK) ::

[atsahqin01]

pphm: bird flu with news
Peregrine's Bavituximab Shows Good Data
Wednesday June 7, 8:06 am ET
Peregrine's Bavituximab Hepatitis C Treatment Shows Promising Early Data in Dosing Trial

TUSTIN, Calif. (AP) -- Peregrine Pharmaceuticals Inc. said Wednesday an early stage clinical trial showed that the biotech drug developer's hepatitis C treatment lowered concentrations of the virus in patients after one dose.

The company said after one high-level dose of bavituximab, half of patients experienced a greater than 75 percent reduction in hepatitis C genetic material in their blood, with a maximum reduction of 97 percent.

After a single dose of the treatment, some patients had a more than 80 percent reduction in the virus after the fourth day, and some had a greater than 60 percent reduction after 12 weeks.

The company also began a second part of the early stage dosing trial, where patients started receiving repeat dosages.

Peregrine shares rose 11 cents, or 6.1 percent, to $1.91 in premarket activity on the INET electronic exchange.